European Commission approves Balversa (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma – Janssen Cilag (J&J)
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission (EC) has approved Balversa (erdafitinib) as a once-daily oral monotherapy for the treatment of adult… read more.